LENZ Therapeutics (LENZ) Competitors $33.91 -0.74 (-2.14%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LENZ vs. DNLI, IBRX, KYMR, VCEL, SWTX, SRRK, IOVA, TWST, CGON, and APGEShould you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include Denali Therapeutics (DNLI), ImmunityBio (IBRX), Kymera Therapeutics (KYMR), Vericel (VCEL), SpringWorks Therapeutics (SWTX), Scholar Rock (SRRK), Iovance Biotherapeutics (IOVA), Twist Bioscience (TWST), CG Oncology (CGON), and Apogee Therapeutics (APGE). These companies are all part of the "biological products, except diagnostic" industry. LENZ Therapeutics vs. Denali Therapeutics ImmunityBio Kymera Therapeutics Vericel SpringWorks Therapeutics Scholar Rock Iovance Biotherapeutics Twist Bioscience CG Oncology Apogee Therapeutics LENZ Therapeutics (NASDAQ:LENZ) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk. Does the media favor LENZ or DNLI? In the previous week, Denali Therapeutics had 4 more articles in the media than LENZ Therapeutics. MarketBeat recorded 7 mentions for Denali Therapeutics and 3 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 1.20 beat Denali Therapeutics' score of 0.61 indicating that LENZ Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is LENZ or DNLI more profitable? Denali Therapeutics' return on equity of -32.94% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LENZ TherapeuticsN/A -58.48% -55.50% Denali Therapeutics N/A -32.94%-30.04% Which has more volatility and risk, LENZ or DNLI? LENZ Therapeutics has a beta of 0.36, suggesting that its share price is 64% less volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Does the MarketBeat Community believe in LENZ or DNLI? Denali Therapeutics received 440 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 67.77% of users gave Denali Therapeutics an outperform vote. CompanyUnderperformOutperformLENZ TherapeuticsOutperform Votes10100.00% Underperform VotesNo VotesDenali TherapeuticsOutperform Votes45067.77% Underperform Votes21432.23% Which has better valuation & earnings, LENZ or DNLI? LENZ Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLENZ TherapeuticsN/AN/A-$124.65MN/AN/ADenali Therapeutics$330.53M10.69-$145.22M-$2.76-8.89 Do insiders and institutionals have more ownership in LENZ or DNLI? 54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 38.4% of LENZ Therapeutics shares are owned by insiders. Comparatively, 7.9% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts rate LENZ or DNLI? LENZ Therapeutics currently has a consensus target price of $35.40, suggesting a potential upside of 4.39%. Denali Therapeutics has a consensus target price of $38.90, suggesting a potential upside of 58.45%. Given Denali Therapeutics' higher probable upside, analysts clearly believe Denali Therapeutics is more favorable than LENZ Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Denali Therapeutics 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73 SummaryDenali Therapeutics beats LENZ Therapeutics on 9 of the 15 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LENZ vs. The Competition Export to ExcelMetricLENZ TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$932.53M$2.93B$5.07B$8.90BDividend YieldN/A1.91%4.99%4.07%P/E RatioN/A16.1687.8613.46Price / SalesN/A282.771,228.8287.66Price / CashN/A169.3839.5136.27Price / Book4.334.436.946.30Net Income-$124.65M-$41.63M$119.12M$225.93M7 Day Performance-0.06%-4.73%-1.84%-1.32%1 Month Performance24.71%-6.53%-3.65%0.60%1 Year PerformanceN/A25.63%31.64%26.23% LENZ Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LENZLENZ Therapeutics0.6756 of 5 stars$33.91-2.1%$35.40+4.4%N/A$932.53MN/A0.00N/APositive NewsDNLIDenali Therapeutics4.4645 of 5 stars$24.55+0.5%$38.90+58.5%+27.3%$3.53B$330.53M0.00364IBRXImmunityBio0.7361 of 5 stars$4.87-0.2%$4.75-2.5%+20.4%$3.39B$620,000.000.00590Positive NewsKYMRKymera Therapeutics1.4071 of 5 stars$43.83-0.5%$52.13+18.9%+110.9%$2.84B$78.59M0.00170Analyst ForecastVCELVericel1.0997 of 5 stars$57.26+2.6%$58.14+1.5%+56.1%$2.83B$197.52M954.49300Analyst ForecastSWTXSpringWorks Therapeutics2.0472 of 5 stars$37.44-1.3%$67.00+79.0%+68.5%$2.79B$5.45M0.00305Analyst ForecastSRRKScholar Rock4.185 of 5 stars$27.86flat$34.00+22.0%+137.1%$2.61B$33.19M-11.86140IOVAIovance Biotherapeutics4.0475 of 5 stars$8.08-0.7%$22.33+176.4%+48.3%$2.46B$1.19M0.00500Options VolumeTWSTTwist Bioscience4.1398 of 5 stars$40.69-1.0%$51.78+27.2%+66.2%$2.42B$312.97M-11.42990Analyst ForecastAnalyst RevisionNews CoverageCGONCG Oncology3.1617 of 5 stars$32.24-1.7%$63.88+98.1%N/A$2.18B$200,000.000.0061Short Interest ↓Analyst RevisionPositive NewsAPGEApogee Therapeutics2.4639 of 5 stars$45.14+0.2%$78.50+73.9%+149.9%$2.03BN/A0.0091 Related Companies and Tools Related Companies DNLI Competitors IBRX Competitors KYMR Competitors VCEL Competitors SWTX Competitors SRRK Competitors IOVA Competitors TWST Competitors CGON Competitors APGE Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LENZ) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
